| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2023 | 21.05% | BMO Capital | $26 → $28 | Upgrades | Market Perform → Outperform |
| 06/01/2023 | 16.73% | Barclays | $28 → $27 | Maintains | Overweight |
| 04/28/2023 | 12.41% | B of A Securities | → $26 | Upgrades | Neutral → Buy |
| 04/28/2023 | 21.05% | Barclays | $29 → $28 | Maintains | Overweight |
| 04/27/2023 | 8.08% | Stephens & Co. | → $25 | Reiterates | → Equal-Weight |
| 04/14/2023 | 12.41% | BMO Capital | → $26 | Reinstates | → Market Perform |
| 02/09/2023 | -0.56% | Stephens & Co. | → $23 | Maintains | Equal-Weight |
| 10/25/2022 | 25.38% | Barclays | $36 → $29 | Maintains | Overweight |
| 10/18/2022 | 21.05% | Goldman Sachs | $32 → $28 | Maintains | Neutral |
| 07/29/2022 | 55.64% | Barclays | $32 → $36 | Maintains | Overweight |
| 03/15/2022 | 21.05% | Barclays | → $28 | Reinstates | → Overweight |
| 03/10/2022 | 29.7% | BMO Capital | → $30 | Upgrades | Market Perform → Outperform |
| 02/18/2022 | 51.32% | Stephens & Co. | → $35 | Upgrades | Equal-Weight → Overweight |
| 06/03/2021 | 21.05% | Barclays | $25 → $28 | Maintains | Overweight |
| 02/08/2021 | 8.08% | Stephens & Co. | $20 → $25 | Upgrades | Equal-Weight → Overweight |
| 10/30/2020 | -4.89% | Barclays | → $22 | Upgrades | Equal-Weight → Overweight |
| 06/29/2020 | -13.53% | Barclays | → $20 | Downgrades | Overweight → Equal-Weight |
| 06/29/2020 | -9.21% | BMO Capital | $36 → $21 | Downgrades | Outperform → Market Perform |
| 03/31/2020 | 21.05% | Barclays | $33 → $28 | Maintains | Overweight |
| 02/24/2020 | 16.73% | Stephens & Co. | $35 → $27 | Reiterates | → Equal-Weight |
| 02/21/2020 | 29.7% | CFRA | $35 → $30 | Downgrades | Strong Buy → Buy |
| 01/16/2020 | 51.32% | Stephens & Co. | → $35 | Downgrades | Overweight → Equal-Weight |
| 10/25/2019 | 38.35% | B of A Securities | → $32 | Initiates Coverage On | → Neutral |
| 08/20/2019 | 55.64% | BMO Capital | $31 → $36 | Upgrades | Market Perform → Outperform |
| 08/02/2019 | 47% | Mizuho | $30 → $34 | Maintains | Buy |
| 03/05/2019 | 12.41% | Stephens & Co. | → $26 | Initiates Coverage On | → Overweight |
What is the target price for Pilgrims Pride (PPC)?
The latest price target for Pilgrims Pride (NASDAQ: PPC) was reported by BMO Capital on July 13, 2023. The analyst firm set a price target for $28.00 expecting PPC to rise to within 12 months (a possible 21.05% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pilgrims Pride (PPC)?
The latest analyst rating for Pilgrims Pride (NASDAQ: PPC) was provided by BMO Capital, and Pilgrims Pride upgraded their outperform rating.
When is the next analyst rating going to be posted or updated for Pilgrims Pride (PPC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pilgrims Pride, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pilgrims Pride was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.
Is the Analyst Rating Pilgrims Pride (PPC) correct?
While ratings are subjective and will change, the latest Pilgrims Pride (PPC) rating was a upgraded with a price target of $26.00 to $28.00. The current price Pilgrims Pride (PPC) is trading at is $23.13, which is out of the analyst's predicted range.